Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Xolair’s Re-Pricing Decided, but Regulators and Novartis Were at Odds over Patient Projections
March 2, 2020
- Crysvita Gets FDA’s Priority Review for Tumor-Induced Osteomalacia
March 2, 2020
- Takeda Files Midazolam Oral Solution for Status Epilepticus
March 2, 2020
- Takeda Submits Brigatinib in Japan as Second-Line Treatment for ALK-Positive NSCLC
March 2, 2020
- Pfizer Sales Reps Told to Avoid Doctor Visits, Stay at Home amid Coronavirus Woes
March 2, 2020
- Nichi-Iko Takes Over Marketing Authorization for Etanercept Biosimilar from Kyowa
March 2, 2020
- Otsuka Joins Global Partnership to Eliminate TB
March 2, 2020
- Seikagaku to Acquire Canadian CDMO; Share Transfer Expected by End of March
March 2, 2020
- Takeda Snaps Up PvP Biologics, Gets Another Celiac Disease Drug
February 28, 2020
- Gilead Launches PIII Studies for Remdesivir for COVID-19, Japan Included
February 28, 2020
- Taiho Gains Japan/Asian Rights to Arcus’ Anti-PD-1 Antibody
February 28, 2020
- Opdivo Filed for 1st-Line NSCLC as Chemo Combo
February 28, 2020
- Vimpat Filed for Adjunctive Therapy for Tonic-Clonic Seizures: UCB/Daiichi Sankyo
February 28, 2020
- Hisamitsu Applies for Diclofenac Patch for Cancer Pain in Japan
February 28, 2020
- Novo Nordisk Submits Somapacitan in Japan for Adult Growth Hormone Deficiency
February 28, 2020
- MSD Japan Embarking on 2-Step Spinoff for Women’s Health, Legacy Brands
February 28, 2020
- Japan Drug Makers Fearing Manufacturing Crisis as Coronavirus Spreads
February 27, 2020
- Fujifilm Receives Avigan Supply Requests from Overseas amid Coronavirus Outbreak
February 27, 2020
- Keytruda No. 1 Drug Prescribed at Acute-Care Hospitals in 2019: Survey
February 27, 2020
- AbbVie Files Humira for Pyoderma Gangrenosum in Japan
February 27, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…